Physician profile
Cathrine E Moizeau
NPI 1205866613
$13,329.11
in general payments reported to CMS, 2019-2025
23 companies · $743 in 2025
The $743 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,568 · 2020: $2,557 · 2021: $2,358 · 2022: $1,033 · 2023: $908 · 2024: $1,162 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,706.64 | 2019-2025 | Livdelzi |
| Abbvie INC. | $4,842.19 | 2019-2025 | |
| Novo Nordisk INC | $488.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $226.66 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $160.17 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $149.72 | 2024 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.84 | 2019-2023 | Jardiance |
| Alk-Abello, INC | $125.29 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Hologic Sales and Service, LLC | $78.31 | 2019-2025 | Aptima |
| Pfizer INC. | $59.57 | 2023-2025 | |
| Exact Sciences Corporation | $57.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $53.89 | 2022-2023 | |
| Vbi Vaccine (Delaware) INC. | $50.38 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $40.22 | 2019-2023 | Breztri |
| Scilex Pharmaceuticals INC. | $36.58 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.51 | 2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.27 | 2024 | Xifaxan |
| Dynavax Technologies Corporation | $17.07 | 2020 | |
| Qiagen, LLC | $15.87 | 2019 | |
| Cranial Technologies, INC | $15.54 | 2025 | Doc Band |
| Organon LLC | $14.62 | 2023 | Nexplanon |
| Sunovion Pharmaceuticals INC. | $13.08 | 2019 | |
| Merck Sharp & Dohme LLC | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathrine Moizeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.